Safety of long-term PPI therapy.

Proton pump inhibitors have become the mainstay of medical treatment of acid-related disorders. Long-term use is becoming increasingly common, in some cases without a proper indication. A large number of mainly observational studies on a very wide range of possible associations have been published in the past decade and are critically reviewed in this article and the existing evidence is evaluated and translated into possible clinical consequences. Based on the existing evidence the benefits of PPI treatment seem to outweigh potential risks in the large majority of patients especially if PPI use is based on a relevant indication. The concern for complications should primarily be directed at elderly, malnourished with significant co-morbidity. In this population an increased risk for enteric infections, fractures and nutritional deficiencies might have clinical consequences and should lead to a careful evaluation of the indication for PPI treatment.

[1]  D. Coppola,et al.  Proton pump inhibitor-associated gastric polyps: a retrospective analysis of their frequency, and endoscopic, histologic, and ultrastructural characteristics. , 1998, American journal of clinical pathology.

[2]  J. Hoenderop,et al.  Systematic review: hypomagnesaemia induced by proton pump inhibition , 2012, Alimentary pharmacology & therapeutics.

[3]  S. Bandinelli,et al.  Proton pump inhibitors and risk of 1-year mortality and rehospitalization in older patients discharged from acute care hospitals. , 2013, JAMA internal medicine.

[4]  J. Rood,et al.  Influence of Gastric Acid on Susceptibility to Infection with Ingested Bacterial Pathogens , 2007, Infection and Immunity.

[5]  J. Powell,et al.  Proton pump inhibitors suppress absorption of dietary non-haem iron in hereditary haemochromatosis , 2007, Gut.

[6]  C. Reimer,et al.  Proton-pump inhibitor therapy induces acid-related symptoms in healthy volunteers after withdrawal of therapy. , 2009, Gastroenterology.

[7]  Vivek R. Sharma,et al.  Effect of Omeprazole on Oral Iron Replacement in Patients with Iron Deficiency Anemia , 2004, Southern medical journal.

[8]  G. Leontiadis,et al.  Proton Pump Inhibitors and Risk of Fracture: A Systematic Review and Meta-Analysis of Observational Studies , 2011, The American Journal of Gastroenterology.

[9]  J. Lewis,et al.  Chronic proton pump inhibitor therapy and the risk of colorectal cancer. , 2007, Gastroenterology.

[10]  E. Kuipers,et al.  Proton Pump Inhibitors and the Risk of Colorectal Cancer , 2008, The American Journal of Gastroenterology.

[11]  S. Meuwissen,et al.  Effect of short‐ and long‐term treatment with omeprazole on the absorption and serum levels of cobalamin , 1996, Alimentary pharmacology & therapeutics.

[12]  L. Lundell,et al.  Changes of gastric mucosal architecture during long‐term omeprazole therapy: results of a randomized clinical trial , 2006, Alimentary pharmacology & therapeutics.

[13]  A. Sandvik,et al.  Marked increase in gastric acid secretory capacity after omeprazole treatment. , 1996, Gut.

[14]  Gian Franco Gensini,et al.  Management of Helicobacter pylori infection—the Maastricht IV/ Florence Consensus Report , 2012, Gut.

[15]  D. Adler,et al.  Clostridium difficile-Associated Diarrhea and Proton Pump Inhibitor Therapy: A Meta-Analysis , 2012, The American Journal of Gastroenterology.

[16]  I. Modlin,et al.  A 5‐decade analysis of 13,715 carcinoid tumors , 2003, Cancer.

[17]  Nelis,et al.  Atrophic gastritis during long‐term omeprazole therapy affects serum vitamin B12 levels , 1999, Alimentary pharmacology & therapeutics.

[18]  A. Blum,et al.  Duodenal bacterial overgrowth during treatment in outpatients with omeprazole. , 1994, Gut.

[19]  R. Regal,et al.  Acid Suppressive Therapy Use on an Inpatient Internal Medicine Service , 2006, The Annals of pharmacotherapy.

[20]  E. Kuipers,et al.  Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fundoplication. , 1996, The New England journal of medicine.

[21]  T. Cundy,et al.  Severe hypomagnesaemia in long‐term users of proton‐pump inhibitors , 2008, Clinical endocrinology.

[22]  R. Janssen,et al.  Novel insight in the association between salmonellosis or campylobacteriosis and chronic illness, and the role of host genetics in susceptibility to these diseases , 2007, Epidemiology and Infection.

[23]  R. Slack,et al.  Diabetes mellitus, anti-secretory drugs and other risk factors for campylobacter gastro-enteritis in adults: a case-control study , 1997, Epidemiology and Infection.

[24]  J. Hallas,et al.  Use of anti‐secretory medication: a population‐based cohort study , 2004, Alimentary pharmacology & therapeutics.

[25]  E. Norkus,et al.  Do acid-lowering agents affect vitamin B12 status in older adults? , 2008, Journal of the American Medical Directors Association.

[26]  H. Dupont,et al.  Systematic review: the use of proton pump inhibitors and increased susceptibility to enteric infection , 2011, Alimentary pharmacology & therapeutics.

[27]  M. Loeb,et al.  Meta‐analysis: proton pump inhibitor use and the risk of community‐acquired pneumonia , 2010, Alimentary pharmacology & therapeutics.

[28]  R. Fiocca,et al.  Gastric endocrine cells and gastritis in patients receiving long-term omeprazole treatment. , 1992, Digestion.

[29]  R. Cavallazzi,et al.  Risk of Clostridium difficile Infection With Acid Suppressing Drugs and Antibiotics: Meta-Analysis , 2012, The American Journal of Gastroenterology.

[30]  Gideon Koren,et al.  The Safety of Proton Pump Inhibitors (PPIs) in Pregnancy: A Meta-Analysis , 2009, The American Journal of Gastroenterology.

[31]  T. Strandberg,et al.  Use of proton pump inhibitors and mortality among institutionalized older people. , 2010, Archives of internal medicine.

[32]  P. Siersema,et al.  Proton pump inhibitor therapy predisposes to community‐acquired Streptococcus pneumoniae pneumonia , 2012, Alimentary pharmacology & therapeutics.

[33]  B. Batuwitage,et al.  Inappropriate prescribing of proton pump inhibitors in primary care , 2007, Postgraduate Medical Journal.

[34]  N. Havu,et al.  Partial gastric corpectomy results in hypergastrinemia and development of gastric enterochromaffinlike-cell carcinoids in the rat. , 1991, Gastroenterology.

[35]  Walsh,et al.  Review article: potential gastrointestinal effects of long‐term acid suppression with proton pump inhibitors , 2000, Alimentary pharmacology & therapeutics.

[36]  Jonkers,et al.  Serum gastrin and chromogranin A during medium‐ and long‐term acid suppressive therapy: a case‐control study , 1999, Alimentary pharmacology & therapeutics.

[37]  R. Shangraw,et al.  Nutritional and pharmaceutical aspects of calcium supplementation. , 1987, American pharmacy.

[38]  M. Kuczmarski,et al.  Vitamin B12 Deficiency is Linked with Long-Term Use of Proton Pump Inhibitors in Institutionalized Older Adults: Could a Cyanocobalamin Nasal Spray be Beneficial? , 2010, Journal of nutrition for the elderly.

[39]  R. Slack,et al.  Omeprazole as a risk factor for campylobacter gastroenteritis: case-control study , 1996, BMJ.

[40]  J. Dent,et al.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa. , 2000, Gastroenterology.

[41]  Y. V. van Duynhoven,et al.  Risk factors for Salmonella Enteritidis and Typhimurium (DT104 and non-DT104) infections in The Netherlands: predominant roles for raw eggs in Enteritidis and sandboxes in Typhimurium infections , 2005, Epidemiology and Infection.

[42]  J. R. Graham Gastric polyposis: onset during long‐term therapy with omeprazole , 1992, The Medical journal of Australia.

[43]  E. Kuipers,et al.  A case series of proton pump inhibitor-induced hypomagnesemia. , 2010, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[44]  R. Pounder,et al.  Drug-induced changes of plasma gastrin concentration. , 1990, Gastroenterology clinics of North America.

[45]  Y. V. van Duynhoven,et al.  Risk factors for indigenous Campylobacter jejuni and Campylobacter coli infections in The Netherlands: a case-control study , 2010, Epidemiology and Infection.

[46]  H. Jick,et al.  Proton Pump Inhibitor Use and Risk of Hip Fractures in Patients without Major Risk Factors , 2008, Pharmacotherapy.

[47]  Yu-Xiao Yang,et al.  Long-term proton pump inhibitor therapy and risk of hip fracture. , 2006, JAMA.

[48]  J. Manson,et al.  Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. , 2010, Archives of internal medicine.

[49]  Miriam C J M Sturkenboom,et al.  Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. , 2004, JAMA.

[50]  A. Sandvik,et al.  The enterochromaffin-like (ECL) cell. Physiological and pathophysiological role. , 1993, Acta oncologica.

[51]  M. Howell,et al.  Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. , 2010, Archives of internal medicine.

[52]  K. Abe,et al.  Effect of omeprazole, an inhibitor of H+, K+-ATPase, on bone resorption in humans , 1993, Calcified Tissue International.

[53]  H. Boezen,et al.  Increased risk of fundic gland polyps during long‐term proton pump inhibitor therapy , 2006, Alimentary pharmacology & therapeutics.

[54]  E. Norkus,et al.  Does long-term PPI use result in vitamin B12 deficiency in elderly individuals? , 2008, Nature Clinical Practice Gastroenterology &Hepatology.

[55]  A. Borobia,et al.  Overuse of PPIs in Patients at Admission, During Hospitalisation, and at Discharge in a Terciary Spanish Hospital , 2010 .

[56]  J. Olsen,et al.  Proton pump inhibitors and risk of gastric cancer: a population-based cohort study , 2009, British Journal of Cancer.

[57]  J. Mant,et al.  Mortality study of 18 000 patients treated with omeprazole , 2003, Gut.

[58]  J. Hallas,et al.  Use of proton pump inhibitors and the risk of community-acquired pneumonia: a population-based case-control study. , 2007, Archives of internal medicine.

[59]  A. Rydning,et al.  On‐demand requirements of patients with endoscopy‐negative gastro‐oesophageal reflux disease: H2‐blocker vs. proton pump inhibitor , 2009, Alimentary pharmacology & therapeutics.

[60]  T. Stadtman,et al.  Vitamin B12 , 1971, Science.

[61]  S. Jamal,et al.  The Relationship Between Proton Pump Inhibitor Use and Longitudinal Change in Bone Mineral Density: A Population-Based From the Canadian Multicentre Osteoporosis Study (CaMos) , 2012, The American Journal of Gastroenterology.

[62]  A. Murray,et al.  Effects of proton pump inhibitors on calcium carbonate absorption in women: a randomized crossover trial. , 2005, The American journal of medicine.

[63]  K. McColl,et al.  Rebound hypersecretion after omeprazole and its relation to on-treatment acid suppression and Helicobacter pylori status. , 1999, Gastroenterology.

[64]  N. Sasaki,et al.  Helicobacter pylori infection and the development of gastric cancer. , 2001, The New England journal of medicine.

[65]  H. Sørensen,et al.  Proton pump inhibitor use and risk of colorectal cancer: a population-based, case-control study. , 2007, Gastroenterology.

[66]  Sang Min Park,et al.  Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis , 2011, Canadian Medical Association Journal.

[67]  D. Corley,et al.  Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. , 2010, Gastroenterology.

[68]  S. Hennessy,et al.  Proton-Pump Inhibitor Use and the Risk for Community-Acquired Pneumonia , 2008, Annals of Internal Medicine.

[69]  P. Vestergaard,et al.  Proton Pump Inhibitors, Histamine H2 Receptor Antagonists, and Other Antacid Medications and the Risk of Fracture , 2006, Calcified Tissue International.

[70]  John K Marshall,et al.  Systematic Review of the Risk of Enteric Infection in Patients Taking Acid Suppression , 2007, The American Journal of Gastroenterology.

[71]  E. Kuipers,et al.  Proton pump inhibitors and gastric neoplasia , 2006, Gut.

[72]  F. Sundler,et al.  Lansoprazole and omeprazole have similar effects on plasma gastrin levels, enterochromaffin-like cells, gastrin cells and somatostatin cells in the rat stomach. , 1992, Digestion.

[73]  P. Khazanie,et al.  Omeprazole Therapy Causes Malabsorption of Cyanocobalamin (Vitamin B12) , 1994, Annals of Internal Medicine.

[74]  S. Watson,et al.  The in vitro growth response of primary human colorectal and gastric cancer cells to gastrin , 1989, International journal of cancer.

[75]  D. Reith,et al.  Continuation of Proton Pump Inhibitors from Hospital to Community , 2006, Pharmacy World and Science.

[76]  E. Björnsson,et al.  Dyspeptic Symptom Development After Discontinuation of a Proton Pump Inhibitor: A Double-Blind Placebo-Controlled Trial , 2010, The American Journal of Gastroenterology.

[77]  S. le Cessie,et al.  Long‐term use of proton pump inhibitors and vitamin B12 status in elderly individuals , 2008, Alimentary pharmacology & therapeutics.

[78]  T. Cundy,et al.  Proton pump inhibitors and severe hypomagnesaemia , 2011, Current opinion in gastroenterology.